Penumbra (NYSE:PEN) Reaches New 52-Week Low at $132.00

Penumbra, Inc. (NYSE:PENGet Rating) shares hit a new 52-week low on Tuesday . The company traded as low as $132.00 and last traded at $135.05, with a volume of 6560 shares changing hands. The stock had previously closed at $136.24.

PEN has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Penumbra in a research note on Tuesday, April 19th. They issued a “buy” rating and a $250.00 price target on the stock. Canaccord Genuity Group cut their price target on shares of Penumbra from $335.00 to $244.00 in a research note on Wednesday, February 23rd. Wells Fargo & Company cut their price target on shares of Penumbra from $321.00 to $265.00 in a research note on Wednesday, May 4th. Truist Financial cut their price target on shares of Penumbra from $350.00 to $300.00 in a research note on Wednesday, February 23rd. Finally, Zacks Investment Research raised shares of Penumbra from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $269.13.

The company has a quick ratio of 3.39, a current ratio of 5.31 and a debt-to-equity ratio of 0.03. The company’s 50 day moving average is $199.27 and its 200 day moving average is $231.10. The firm has a market capitalization of $5.30 billion, a price-to-earnings ratio of -788.31 and a beta of 0.61.

Penumbra (NYSE:PENGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.05). Penumbra had a positive return on equity of 1.97% and a negative net margin of 0.83%. The firm had revenue of $203.90 million for the quarter, compared to the consensus estimate of $195.39 million. During the same period in the prior year, the company earned $0.27 EPS. The company’s revenue for the quarter was up 20.5% compared to the same quarter last year. On average, analysts expect that Penumbra, Inc. will post 0.2 EPS for the current year.

In related news, EVP Johanna Roberts sold 1,500 shares of the business’s stock in a transaction on Friday, April 1st. The shares were sold at an average price of $225.32, for a total value of $337,980.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders sold 3,028 shares of company stock worth $682,033. 7.50% of the stock is currently owned by insiders.

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. grew its stake in shares of Penumbra by 4.2% in the fourth quarter. BlackRock Inc. now owns 3,356,220 shares of the company’s stock worth $964,309,000 after purchasing an additional 136,248 shares during the last quarter. William Blair Investment Management LLC grew its stake in shares of Penumbra by 61.5% in the fourth quarter. William Blair Investment Management LLC now owns 1,101,554 shares of the company’s stock worth $316,498,000 after purchasing an additional 419,632 shares during the last quarter. State Street Corp boosted its position in Penumbra by 2.7% during the fourth quarter. State Street Corp now owns 925,717 shares of the company’s stock valued at $265,977,000 after acquiring an additional 24,447 shares during the last quarter. Champlain Investment Partners LLC boosted its position in Penumbra by 7.8% during the fourth quarter. Champlain Investment Partners LLC now owns 470,780 shares of the company’s stock valued at $135,265,000 after acquiring an additional 34,195 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Penumbra by 4.4% during the fourth quarter. Geode Capital Management LLC now owns 428,477 shares of the company’s stock valued at $123,110,000 after acquiring an additional 18,075 shares during the last quarter. 80.50% of the stock is currently owned by institutional investors.

About Penumbra (NYSE:PEN)

Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands.

Featured Stories

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.

Penumbra (NYSE:PEN) Reaches New 52-Week Low at $132.00

Penumbra, Inc. (NYSE:PENGet Rating) shares hit a new 52-week low on Tuesday . The company traded as low as $132.00 and last traded at $135.05, with a volume of 6560 shares changing hands. The stock had previously closed at $136.24.

PEN has been the topic of a number of research reports. Canaccord Genuity Group cut their price target on shares of Penumbra from $335.00 to $244.00 in a research note on Wednesday, February 23rd. StockNews.com initiated coverage on shares of Penumbra in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Truist Financial cut their price target on shares of Penumbra from $350.00 to $300.00 in a research note on Wednesday, February 23rd. Wells Fargo & Company cut their price target on shares of Penumbra from $321.00 to $265.00 in a research note on Wednesday, May 4th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Penumbra in a research note on Tuesday, April 19th. They issued a “buy” rating and a $250.00 price target on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $269.13.

The stock has a market capitalization of $5.30 billion, a price-to-earnings ratio of -788.31 and a beta of 0.61. The company’s fifty day simple moving average is $199.27 and its 200 day simple moving average is $231.10. The company has a quick ratio of 3.39, a current ratio of 5.31 and a debt-to-equity ratio of 0.03.

Penumbra (NYSE:PENGet Rating) last released its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.05). Penumbra had a negative net margin of 0.83% and a positive return on equity of 1.97%. The business had revenue of $203.90 million during the quarter, compared to analyst estimates of $195.39 million. During the same quarter last year, the company posted $0.27 earnings per share. The company’s revenue was up 20.5% on a year-over-year basis. As a group, analysts anticipate that Penumbra, Inc. will post 0.2 earnings per share for the current year.

In related news, EVP Johanna Roberts sold 1,500 shares of the company’s stock in a transaction dated Friday, April 1st. The shares were sold at an average price of $225.32, for a total value of $337,980.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold 3,028 shares of company stock worth $682,033 over the last 90 days. 7.50% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of PEN. Maverick Capital Ltd. acquired a new stake in shares of Penumbra in the 4th quarter valued at approximately $26,000. Moors & Cabot Inc. acquired a new position in shares of Penumbra during the third quarter worth $27,000. CI Investments Inc. bought a new stake in shares of Penumbra in the third quarter worth $40,000. Covestor Ltd bought a new stake in shares of Penumbra in the fourth quarter worth $44,000. Finally, Horan Securities Inc. bought a new stake in shares of Penumbra in the fourth quarter worth $86,000. 80.50% of the stock is owned by institutional investors and hedge funds.

About Penumbra (NYSE:PEN)

Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands.

Featured Stories

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.